Research Interests:
Role of innate immune cells and inflammation in tumor growth Development of new immunotherapy and prognostic biomarkers for ovarian cancerAbout ANM Nazmul Khan
Biography:
Dr. ANM Nazmul Khan joined the staff of Roswell Park Comprehensive Cancer Center (Roswell Park) in 2011 as a Scientist in the Division of Infectious Disease, Department of Medicine. Prior to joining the Department of Medicine he completed post-doctoral training in the Department of Immunology and Molecular Medicine at Roswell Park. In 2022, Dr. Khan was appointed as Research Assistant Professor of Oncology in the Department of Internal Medicine.
Positions
- Assistant Professor of Oncology (Research)
- Department of Internal Medicine
Background
Education and Training:
- 2005 - PhD - Immunology - State University of New York at Buffalo, Buffalo, NY
- 1987 - MBBS - Medicine - Dhaka Medical College, University of Dhaka, Bangladesh
Residency:
- 1988 - Resident Physician - Dhaka Medical College Hospital, Dhaka, Bangladesh
Fellowship:
- 2008 - Post-doctoral - Roswell Park Comprehensive Cancer Center, Buffalo, NY
- 2005 - Pre-doctoral - State University of New York at Buffalo, Buffalo, NY
Professional Memberships:
- American Association of Immunologists
- American Association for Cancer Research
Research
Research Overview:
Dr. Khan’s research interests include the role of innate immune cells (e.g., neutrophils, platelets, macrophages) and damage associated molecular patterns (DAMPs) in tumor growth; overcoming myeloid cell-derived immunosuppression to enhance cancer vaccine efficacy; the mechanisms involved in modulating functional effects of innate immune cells against pathogens or tumor; development of immune-based therapy and prognostic biomarkers for ovarian cancer.
Publications
1. Mark J, Fisher D, Kim M, Emmons T, Khan AN, Alqassim E, Singel K, Mistarz A, Lugade A, Zhan H, Yu H, Segal B, Lele S, Frederick P, Kozbor D, Skitzki J, Odunsi K (2023) Carboplatin enhances lymphocyte-endothelial interactions to promote CD8+ T cell trafficking into the ovarian tumor microenvironment. Gynecol Oncol. 2023; 168: 92 – 99.
2. Segal BH, Giridharan T, Suzuki S, Khan AN, Zsiros E, Emmons TR, Yaffe MB, Gankema AA, Hoogeboom M, Goetschalckx I, Matlung HL, Kuijpers TW (2022) Neutrophil interactions with T cells, Platelets, Endothelial cells, and of course Tumor cells. Immunological Reviews 2022; 00:1-23
3. Khan AN, Emmons TR, Magner WJ, Alqassim E, Singel KL, Ricciuti J, Eng KH, Odunsi K, Tomasi TB, Lee K, Abrams SI, Mesa C and Segal BH (2022) VSSP abrogates murine tumor-associated myeloid cell-driven immune suppression and induces M1 polarization in tumor-associated macrophages from ovarian cancer patients. Cancer Immunol Immunother. 2022 Oct; 71(10):2355 - 2369.
4. Alqassim EY, Sharma S, Khan AN, Emmons T, Cortes-Gomez TE, Alahmari A, Singel KL, Mark J, Davidson BA, McGray AJ, Liu Q, Lichty BD, Moysich KB, Wang J, Odunsi K, Segal BH and Bora E. Baysal BE (2021) RNA editing enzyme APOBEC3A promotes pro-inflammatory (M1) macrophage polarization. Commun. Biol. 2021 January 22; 4(1):102.
5. Emmons TR, Giridharan T, Singel KL, Khan AN, Ricciuti J, Howard K, Toro SL, Debreceni I, Aarts CE, Kuijpers TW, Allen L-A, Ferreira VP, Holland SM, Ram S, Yaffe MB, Lederer JA, Eng KH, Moysich KB, Odunsi K, Zsiros E and Segal BH (2021) Mechanisms driving neutrophil-induced T cell immunoparalysis in ovarian cancer. Cancer Immunol Res. 2021 9 (7): 790-810.
6. Khan AN, Emmons TR, Wong J, Alqassim E, Singel KL, Mark J, Smith B, Joseph D. Tario, Eng K, Moysich KB, Odunsi K, Abrams SI, Segal BH (2020) Quantification of Early-Stage Myeloid-Derived Suppressor Cells in Cancer Requires Excluding Basophils. Cancer Immunol Res 2020 Jun;8(6):819-828.